1. A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis.
   Farnaz Farsi et al, 2021, Eur J Nutr CrossRef
2. Immunoregulation by Artemisinin and Its Derivatives: A New Role for Old Antimalarial Drugs
   Feifei Qiu et al, 2021, Front. Immunol. CrossRef
3. Artemisinin ameliorates intestinal inflammation by skewing macrophages to the M2 phenotype and inhibiting epithelial–mesenchymal transition
   Manxiu Huai et al, 2021, International Immunopharmacology CrossRef
4. Dietary Aflatoxin B1 attenuates immune function of immune organs in grass carp (Ctenopharyngodon idella) by modulating NF-κB and the TOR signaling pathway
   Xiang-Ning He et al, 2022, Front. Immunol. CrossRef
5. Therapeutic potential of artemisinin and its derivatives in managing kidney diseases
   Qi Jin et al, 2023, Front. Pharmacol. CrossRef
6. The protective effect of Teprenone in TNBS-induced ulcerative colitis rats by modulating the gut microbiota and reducing inflammatory response
   Jianfeng Yao et al, 2024, Immunopharmacology and Immunotoxicology CrossRef
7. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease
   Mohammad Aadil Bhat et al, 2024, CRCEP CrossRef
8. Harnessing nature’s pharmacy: investigating natural compounds as novel therapeutics for ulcerative colitis
   You Huang et al, 2024, Front. Pharmacol. CrossRef
9. Artesunate alleviates radiation‐induced submandibular gland epithelial cell damage in rats by reducing inflammation and apoptosis
   Yuchen Wang et al, 2024, Cell Biology International CrossRef
10. Anti-inflammatory, anti-colitis, and antioxidant effects of columbianadin against DSS-induced ulcerative colitis in rats via alteration of HO-1/Nrf2 and TLR4-NF-κB signaling pathway
    Yanping Zhang et al, 2025, Inflammopharmacol CrossRef